It has recently found that AZD1222 could induce a robust humoral, CD8 and Th1 dominant CD4 response in mice and rhesus macaques and that both a prime and a prime-boost regimen protected rhesus macaques against COVID-19 related pneumonia. Here, CD4 is linked to COVID-19.